

## Data Sheet

### CD155 / TCR Activator - CHO Recombinant Cell line Cat. #: 60548

#### Product Description

Recombinant CHO-K1 cells constitutively expressing human CD155 (Poliovirus receptor, Nectin-like protein 5, GenBank accession # NM\_006505) and an engineered T cell receptor (TCR) activator.

#### Background

TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory T cells. Interaction with the poliovirus receptor (PVR; CD155) on antigen presenting cells, such as dendritic cells, recruits Src homology (SH) domain-containing protein tyrosine phosphatase SHP1 and SHP2 or the inositol phosphatases SHIP1 and SHIP2 to the TIGIT ITIM domain. This increases IL-10 release and suppresses NF- $\kappa$ B and NFAT T cell receptor (TCR) signaling, which blocks T cell proliferation and cytokine production. TIGIT serves as a competitive inhibitor of CD226, a co-stimulatory receptor for CD155. TIGIT-targeting antibodies that block these T cell-intrinsic inhibitory effects have shown enhanced anti-tumor and anti-viral functions in preclinical studies.

#### Applications

- Screen for activators or inhibitors of TIGIT signaling in a cellular context
- Screen CD155 antibodies for binding affinity
- Characterize the biological activity of TIGIT or CD226 interactions with CD155

#### Format

Each vial contains  $\sim 2 \times 10^6$  cells in 1 ml of 10% DMSO

#### Storage

Immediately upon receipt, store in liquid nitrogen.

#### Mycoplasma Testing

The cell line has been screened using the PCR-based Venor<sup>®</sup>GeM Mycoplasma Detection kit (Sigma-Aldrich, #MP0025) to confirm the absence of *Mycoplasma* species.

#### General Culture Conditions

**Thaw Medium 3 (#60186):** Ham's F-12 medium (Hyclone, #SH30526.01) supplemented with 10% FBS (Life technologies #26140-079), 1% Penicillin/Streptomycin (Hyclone, #SV30010.01).

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

AMSBIO | [www.amsbio.com](http://www.amsbio.com) | [info@amsbio.com](mailto:info@amsbio.com)

 **UK & Rest of the World**  
184 Park Drive, Milton Park  
Abingdon, UK  
T: +44 (0)1235 828 200  
F: +44 (0) 1235 820 482

 **North America**  
1035 Cambridge Street,  
Cambridge, MA 02141  
T: +1 (617) 945-5033 or  
T: +1 (800) 987-0985  
F: +1 (617) 945-8218

 **Germany**  
Bockenheimer Landstr. 17/19  
60325 Frankfurt/Main  
T: +49 (0) 69 779099  
F: +49 (0) 69 13376880

 **Switzerland**  
Centro Nord-Sud 2E  
CH-6934 Bioggio-Lugano  
T: +41(0) 91 604 55 22  
F: +41(0) 91 605 17 85

**Complete Growth Medium:** Thaw Medium 3 ( #60186) plus 500 µg/ml of Hygromycin B (Hyclone #SV30070.01) and 5 µg/ml of Puromycin (Invivogen # ant-pr-1).

Cells should be grown at 37°C with 5% CO<sub>2</sub> using the complete growth medium to ensure recombinant expression. CD155 / TCR activator– CHO cells should exhibit a typical cell division time of ~24 hours.

**To thaw the cells,** it is recommended to quickly thaw the frozen cells from liquid nitrogen in a 37°C water-bath, transfer to a tube containing 10 ml of Thaw Medium 3 (**no Hygromycin B, no Puromycin**), spin down cells at 1000 rpm, and resuspend cells in 5 ml of pre-warmed Thaw Medium 3 (**no Hygromycin B, no Puromycin**). Transfer resuspended cells to a T25 flask and culture at 37°C in a 5% CO<sub>2</sub> incubator overnight. The next day, replace the medium with fresh warm Thaw Medium 3 (**no Hygromycin B, no Puromycin**), and continue growing culture in a CO<sub>2</sub> incubator at 37°C until the cells are ready to be split. Cells should be split before they reach complete confluence. At first passage switch to complete growth medium (**contains Hygromycin B and Puromycin**).

**To passage the cells,** rinse cells with phosphate buffered saline (PBS), then detach cells from culture vessel with 0.05% Trypsin/EDTA. After detachment, add complete growth medium and transfer to a tube. Spin down cells, resuspend cells in complete growth medium (**contains Hygromycin B and Puromycin**) and seed appropriate aliquots of cell suspension into a new culture vessels. Sub cultivation ration: 1:10 to 1:20 twice a week.

**To freeze down the cells,** rinse cells with phosphate buffered saline (PBS), and detach cells from culture vessel with 0.05% Trypsin/EDTA. After detachment, add Thaw Medium 3 (**no Hygromycin B, no Puromycin**) and count the cells, then transfer to a tube, spin down cells, and resuspend in 4°C Freezing Medium (10% DMSO + 90% FBS) to ~2x10<sup>6</sup> cells/ml. Dispense 1 ml of cell aliquots into cryogenic vials. Place vials in an insulated container for slow cooling and store at -80°C overnight. Transfer to liquid nitrogen the next day for storage. It is recommended to expand the cells and freeze down more than 10 vials of cells for future use at an early passage.


### **Functional Validation and Assay Performance**

Expression of human CD155 in CD155/TCR Activator-CHO cells was confirmed by FACS.

The functionality of the cell line was validated using a TIGIT:CD155 cell-based assay. In this assay, TIGIT/NFAT Reporter/Jurkat T cells (BPS Bioscience, #60538) are used as effector cells; the CD155/TCR Activator - CHO cells are used as target cells. When these two cells are co-cultivated, NFAT luciferase reporter in the effector cells is activated by the engagement of TCR complexes with TCR activator on the target cells and the engagement of the co-stimulatory receptor CD226 with CD155 on target cells. However TIGIT can compete with CD226 for binding to CD155, therefore, TIGIT and CD155 binding suppresses the NFAT-responsive luciferase activity. This inhibition can be specifically reversed by anti-TIGIT neutralizing antibody.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

The neutralizing antibody blocks TIGIT:CD155 interaction and promotes T cell activation, resulting in reactivation of the NFAT responsive luciferase reporter.




**Figure 1. Anti-TIGIT neutralizing antibody induced NFAT luciferase reporter activity in TIGIT/NFAT Reporter-Jurkat cells co-cultured with CD155/TCR Activator-CHO cells.**


CD155/TCR Activator-CHO cells or TCR Activator-CHO cells ( #60539) were seeded in 96-well plate. The next day, cells were incubated with anti-TIGIT neutralizing antibody ( #71210) and TIGIT/NFAT Reporter-Jurkat cells ( #60538) or control NFAT Reporter – Jurkat cells ( #60621). After incubation, ONE Step™ Luciferase reagent ( #60690) was added to the cells to measure NFAT activity.

The fold induction is equal to background-subtracted luminescence of antibody-treated well/background-subtracted luminescence of untreated-control wells of each respective cell line.

- A. Anti-TIGIT neutralizing antibody induced NFAT luciferase reporter activity in TIGIT/NFAT Reporter-Jurkat cells, but not in control NFAT Reporter-Jurkat cells, when co-cultured with CD155/TCR Activator-CHO cells




B. Anti-TIGIT neutralizing antibody induced NFAT luciferase reporter activity in TIGIT/NFAT Reporter-Jurkat cells when co-cultured with CD155/TCR Activator-CHO cells, but not with control TCR Activator-CHO cells.



**Figure 2. FACS analysis of cell surface expression of CD155 in CD155/TCR Activator-CHO cells.**

CD155/TCR Activator cells or control CHO cells were stained with PE-labeled anti-CD155 antibody (Biolegend, #337610) and analyzed by FACS. Y-axis is the % cell number. X-axis is the intensity of PE.



	Samples	Subset	Cell Count
■	CD155/TCR Activator-CHO	Live singlet	10207
■	Control CHO	Live singlet	10116

**Sequence**

Human CD155 sequence (accession #NM\_006505)

MARAMAAAWPLLLLVALLLVLSWPPPGTGDVVVVQAPTQVPGFLGDSVTLPCYLQVPNMEVTHVSQ  
 TWARHGESGSMVAFHQQTQGPSYSESKRLEFVAARLGAELRNASLRMFGLRVEDEGNYTCLFVTF  
 PQGSRSDIWLRLVLAKPQNTAEVQKVQLTGEVPMARCVSTGGRPPAQITWHSDLGGMPNTSQV  
 PGFLSGT VTVTSLWILVPSSQVDGKNVTCKVEHESFEK PQLLTVNLT VYYPPEVSI S GYDNNWY  
 LGQNEATLTCDARSNPEPTGYNWSTTMG LPPFAVAQGAQLLIRPVDKPIINTT LICNVTNALGA  
 RQAE LTVQVKEGPPSEHSGMSRNAIIFLV LGILVFLILLGIGIYFYWSKCSREVLWHCHLCPSS  
 TEHASASANGHVSYS AVSRENSSSQDPQTEGTR

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

## Related Products

<b>Product</b>	<b>Cat. #</b>	<b>Size</b>
TIGIT/NFAT Reporter-Jurkat recombinant cell line	60538	2 vials
TCR activator-CHO cell line	60539	2 vials
NFAT Reporter – Jurkat cell line	60621	2 vials
Thaw Medium 2	60184	100 ml
Thaw Medium 3	60186	100 ml
Anti-TIGIT neutralizing antibody	71210	100 µg
ONE-Step™ Luciferase Assay System	60690-1	10 ml
ONE-Step™ Luciferase Assay System	60690-2	100 ml
Human CD155 (PVR) His-tag Protein	71181	100 µg
Mouse CD155 (PVR) His-tag Protein	71167	100 µg
Mouse CD155, His-tag, Biotin-labeled	71168	50 µg
Human CD226, Fc fusion	71252	100 µg
Human CD226, Fc fusion, Biotin-labeled	71253	50 µg
Human CD112, Fc fusion	71197	100 µg
Human CD112, Fc fusion, Biotin-labeled	71234	50 µg
Human TIGIT, Fc fusion	71186	100 µg
Human TIGIT, Fc fusion, Biotin-labeled	71251	50 µg
TIGIT:CD155 Homogenous Assay Kit	72029	384 reactions
CD226: CD155 Homogenous Assay Kit	72052	384 reactions
TIGIT:CD112 Homogenous Assay Kit	72030	384 reactions
CD226: CD112 Homogenous Assay Kit	72051	384 reactions

## License Disclosure

Purchase of this cell line grants you with a 10-year license to use this cell line in your immediate laboratory, for research use only. This license does not permit you to share, distribute, sell, sublicense, or otherwise make the cell line available for use to other laboratories, departments, research institutions, hospitals, universities, or biotech companies. The license does not permit use of this cell line in humans or for therapeutic or drug use. The license does not permit modification of the cell line in any way. Inappropriate use or distribution of this cell line will result in revocation of the license and result in an immediate cease of sales and distribution of BPS Bioscience products to your laboratory. BPS Bioscience does not warrant the suitability of the cell line for any particular use, and does not accept any liability in connection with the handling or use of the cell line. Modifications of this cell line, transfer to another facility, or commercial use of the cells may require a separate license and additional fees; contact [sales@bpsbioscience.com](mailto:sales@bpsbioscience.com) for details. Publications using this cell line should reference BPS Bioscience, Inc., San Diego.

OUR PRODUCTS ARE FOR RESEARCH USE ONLY. NOT FOR DIAGNOSTIC OR THERAPEUTIC USE.

AMSBIO | [www.amsbio.com](http://www.amsbio.com) | [info@amsbio.com](mailto:info@amsbio.com)

 **UK & Rest of the World**  
184 Park Drive, Milton Park  
Abingdon, UK  
T: +44 (0)1235 828 200  
F: +44 (0) 1235 820 482

 **North America**  
1035 Cambridge Street,  
Cambridge, MA 02141  
T: +1 (617) 945-5033 or  
T: +1 (800) 987-0985  
F: +1 (617) 945-8218

 **Germany**  
Bockenheimer Landstr. 17/19  
60325 Frankfurt/Main  
T: +49 (0) 69 779099  
F: +49 (0) 69 13376880

 **Switzerland**  
Centro Nord-Sud 2E  
CH-6934 Bioggio-Lugano  
T: +41(0) 91 604 55 22  
F: +41(0) 91 605 17 85